Does Multimedia Have An Impact On Clinical Trial Success?

As a concept, eConsent has been around for nearly two decades, growing in use and efficiency since its early days. While there has been an uptick in the adoption of digital consent in recent years, even before COVID, companies were beginning to use the technology more often. In 2016, the FDA published its eConsent guidance¹, which indicates that there was already significant momentum around its use.

Additional research by the Tufts Center for the Study of Drug Development (CSDD) reported ² that prior to the pandemic, about 41% of respondents from various biopharmaceutical companies and CROs used eConsent in their clinical trials eConsent use among biopharmaceutical companies and CROs, while 65% use eConsent now, and an additional 37% plan to use it in the future—meaning that nearly everyone in the industry is either already using eConsent or planning to soon.

With the possibilities of digital consent only just beginning to be explored, learn how eConsent could have a positive impact on clinical trials as the technology continues to evolve.